The present invention provides a composition that enables measurement of glycated hemoglobin in the presence of a stronger surfactant than conventional surfactants. To this end, the present invention provides an amadoriase in which one or more amino acids have been substituted at positions corresponding to positions selected from the group consisting of positions 80, 71, 175, 172, 279, 12, 9, 77, 30, 28, 13, 3, 4, 286, 204, 338, 44, 340, and 194 of the amadoriase derived from the genus Coniochaeta having the amino acid sequence as shown in SEQ ID NO: 1 as well as a composition for measurement of glycated hemoglobin comprising an amadoriase that retains activity in the presence of an anionic surfactant. The present invention can provide an enzyme and a composition for measurement of glycated hemoglobin that sufficiently remain stable even when exposed to anionic surfactants.

Systems and methods are provided for determining the age of cellular hemoglobin in individual red blood cells in a blood sample by determining the percentage of HbA1c. In embodiments, a method includes measuring side scatter and fluorescence of the individual red blood cells and identifying immature red blood cells and mature red blood cells from the side scatter and fluorescence measurement. In embodiments, data collected includes the exact number of red blood cells, the fraction limits in fluorescence and side scatter units, the mean value of each fraction in fluorescence and side scatter units, the mean FL1 values per fraction in arbitrary units and the mean side scatter values per fraction in arbitrary units. In embodiments, a method also includes deriving a HbA1c content from the measured mean fluorescence of the individual red blood cells and determining the percentage of HbA1c from the HbA1c content and the hemoglobin content of the red blood cells.

A measurement method includes a measurement step of measuring a first single value and a second signal value, the first signal value being based on a reaction between a first reacting substance and the sample, the second signal value being based on a reaction between a second reacting substance and the sample, the first reacting substance having a higher reactivity to a second detection target than to a first detection target, the second reacting substance having a higher reactivity to the first detection target than to the second detection target.

Methods for identifying a patient who is eligible for an intensification of heart failure therapy are disclosed. Furthermore, methods for optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy are disclosed. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described methods.

Biosensor system measurement devices used to determine the presence and/or concentration of an analyte in a sample include normalized calibration information relating output signal or signals the device generates in response to the analyte concentration of the sample to previously determined reference sample analyte concentrations. The measurement devices use this normalized calibration information to relate one or more output signals from an electrochemical or optical analysis of a sample to the presence and/or concentration of one or more analytes in the sample. The normalized calibration information includes a normalization relationship to normalize output signals measured by the measurement device of the biosensor system and at least one normalized reference correlation relating normalized output signals to reference sample analyte concentrations.

A system for monitoring a physiological condition of a user includes a first measuring apparatus for personal use, a second measuring apparatus for use by medical professionals, and a server. The first measuring apparatus measures a first physiological parameter of the user. The second measuring apparatus measures a second physiological parameter of the user. The server receives the first and second physiological parameters measured by the first and second measuring apparatuses. The measured values of the first and second physiological parameters are associated with a disease condition, a health condition, a nutrient intake condition, a fitness condition or an exercise condition of the user.

The present invention relates to the field of biological sample testing technology, and in particular, to a biological sample reaction vessel. A reagent storage portion and a push rod movable relative to the reagent storage portion are packaged in the reaction vessel; the reagent storage portion comprises at least one reagent containing cavity, and the reagent containing cavity is sealed by a sealing element; and the push rod is connected to the sealing element, and the push rod is used for cooperation with an external device to separate the sealing element from the reagent storage portion. In this application, the reagent storage portion and the push rod are both packaged in the biological sample reaction vessel, and in reaction, the biological sample reaction vessel only needs to cooperate with a test cassette. With one operation, that is, inserting the biological sample reaction vessel into the external device, the reagent in the reagent storage portion can be released rapidly.

The present invention relates to the optical measurement of blood analytes, such as glycated hemoglobin (HbA1c) and serum albumin as a functional metric of mean blood glucose in the diagnosis of diabetic patients. Non-enhanced Raman spectroscopy is employed as the analytical method for quantitative detection of blood analytes. Using processing techniques, non-enzymatic glycosylation (glycation) of the analytes results in measurable and highly reproducible changes in the acquired spectral data, which enable the accurate measurements and classification of glycated and unglycated analytes.

The present invention provides a method for measuring glycated hemoglobin in a sample, which comprises directly oxidizing glycated hemoglobin in a sample, and then measuring a substance produced or consumed by the oxidation; and a method for measuring glycated hemoglobin in a sample, which comprises directly oxidizing glycated hemoglobin in a sample using an enzyme, and then measuring a substance produced or consumed by the oxidation. A method for measuring glycated hemoglobin of the present invention is useful for diagnosing lifestyle-related disease such as diabetes mellitus.

Object An object of the present invention is to provide a highly stable FVHO preparation and a low-hygroscopicity dried FVHO preparation. Means for achieving the object A method for producing a FVHO preparation comprising a step of allowing at least one member selected from phosphoric acid, casein peptone, D-glucosamine hydrochloride, melibiose, sorbose, lactose, fructose, melezitose, glucono-1,5-lactone, and ribitol; and a method for producing a dried FVHO preparation, comprising a step of allowing Bicine to coexist.